Effect of experimental gestational diabetes and administration of glibenclamide on mRNA level of NLRP3-inflammasome and distribution of NLRP3+-cells in mesenteric lymph nodes in progeny

Authors

  • Т. М. Prozorova Zaporizhzhia State Medical University, Ukraine,
  • V. A. Kamyshna Zaporizhzhia State Medical University, Ukraine,
  • О. М. Kamyshnyi Zaporizhzhia State Medical University, Ukraine, https://orcid.org/0000-0003-3141-4436

DOI:

https://doi.org/10.14739/2310-1237.2017.2.109269

Keywords:

EGD, MLN, NLRP3-inflammasome, glibenclamide

Abstract

A number of dysfunctions of congenital and adaptive components of the immune system are observed in progeny of rats with experimental gestational diabetes (EGD). The key link in pathogenesis of EGD and other diseases is the activation of NLRP3-inflammasome. Therefore, it is an attractive target for pharmaceutical effects. Among the numerous inhibitors of the inflammasome, glibenclamide is the most promising drug, which can effectively correct hyperglycemia in pregnant women.

The aim of the study was to determine the level of mRNA expression of NLRP3-inflammasome and the distribution of NLRP3+-cells in mesenteric lymph nodes in progeny of rats with experimental gestational diabetes and after administration of glibenclamide to pregnant Wistar rats.

Materials and methods. A molecular-genetic study was carried out using polymerase chain reaction with real-time reverse transcription (RT–PCR) of mRNA expression level of the Nlrp3 gene. The distribution of NLRP3+-cells in MLN of experimental animals was investigated by immunofluorescence and immunohistochemical methods.

Results. The development of EGD is accompanied by transcriptional induction of the Nlrp3 gene in MLN in descendants, whose mRNA level increased five-fold (p < 0.05) in 1-month and 3-fold (p < 0.05) in 6-month-old animals. The administration of glibenclamide to pregnant rats inhibited the transcription of the Nlrp3 gene only at the age of 1 month (5.3 times, p < 0.05) and did not change it in the older age group. In the progeny of rats with EGD, the density of the NLRP3+-lymphocyte population in the MLN increased, more clearly at early observation times. The intake of glibenclamide reduced the number of NLRP3+-lymphocytes only at the age of 1 month (by 33 %, the cortex plateau), whereas their number in the medullary cords of 6-month-old progeny even increased.

Conclusion. The increased mRNA expression of NLRP3-inflammasome and density of NLRP3+-cells in MLN in descendants of rats with EGD indicates activation of pro-inflammatory signaling. Glibenclamide, as an inhibitor of the activation of the NLRP3-inflammasome, demonstrated its effectiveness only at early observation times.

References

Kamyshny, A. M., Prozorova, T. M., & Kamyshna, V. A. (2015). Vliyanie e´ksperimental'nogo gestacionnogo diabeta na uroven' e´kspressii mRNK AIRE i kharakter differencirovki FOXP3+ kletok v bryzheechnyh limfaticheskikh uzlakh [The influence of experimental gestational diabetes on expression of Aire mRNA and character of differentiation of Foxp3+ - cells in mesenteric lymph nodes in the offspring]. Morfolohiia, 9(2), 29–35. [in Russian].

Prozorova, T. M., & Kamyshnyy, O. M. (2016). Zminy rivnia ekspresii mRNK heniv AIRE, DEAF1, FOXP3,CTLA4 i IL10 v bryzhovykh limfatychnykh vuzlakh u nashchadkiv shchuriv z eksperymentalnym hestatsiinym diabetom i v umovakh formuvannia oralnoi tolerantnosti do insulinu [Changes of mRNA gene expression level of AIRE, DEAF1, FOXP3, CTLA4 and IL-10 in the offspring of rats with experimental gestational diabetes and in conditions of insulin oral tolerance formation]. Problemy endokrynnoi patolohii, 3, 50–59. [in Ukrainian].

Wojcik, M., Zieleniak, A., Zurawska-Klis, M., Cypryk, K., & Wozniak, L. (2016). Increased expression of immune-related genes in leukocytes of patients with diagnosed gestational diabetes mellitus (GDM). Experimental Biology And Medicine, 241(5), 457–465. doi: 10.1177/1535370215615699.

Li, Q., Pereira, T., Moyce, B., Mahood, T., Doucette, C., Rempel, J., & Dolinsky, V. (2016). In utero exposure to gestational diabetes mellitus conditions TLR4 and TLR2 activated IL-1beta responses in spleen cells from rat progeny. Biochimica Et Biophysica Acta (BBA) – Molecular Basis Of Disease, 1862(11), 2137–2146. doi: 10.1016/j.bbadis.2016.08.004.

Jo, E., Kim, J., Shin, D., & Sasakawa, C. (2015). Molecular mechanisms regulating NLRP3 inflammasome activation. Cellular And Molecular Immunology, 13(2), 148–159. doi: 10.1038/cmi.2015.95.

Lappas, M. (2014). Activation of inflammasomes in adipose tissue of women with gestational diabetes. Molecular And Cellular Endocrinology, 382(1), 74–83. doi: 10.1016/j.mce.2013.09.011.

Coll, R., Robertson, A., Chae, J., Higgins, S., Muñoz-Planillo, R., Inserra, M. et al. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21(3), 248–55. doi: 10.1038/nm.3806.

Netea, M., & Joosten, L. (2015). Inflammasome Inhibition: Putting Out the Fire. Cell Metabolism, 21(4), 513–514. doi: http://dx.doi.org/10.1016/j.cmet.2015.03.012.

Shao, B., Xu, Z., Han, B., Su, D., & Liu, C. (2015). NLRP3 inflammasome and its inhibitors: a review. Frontiers In Pharmacology, 6, 262. doi: 10.3389/fphar.2015.00262.

Berggren, E. K., & Boggess, K. A. (2013). Oral Agents for the Management of Gestational Diabetes. Clinical Obstetrics And Gynecology, 56(4), 827–836. doi: 10.1097/GRF.0b013e3182a8e0a5.

Bimson, B., Rosenn, B., Morris, S., Sasso, E., Schwartz, R., & Brustman, L. (2016). Current trends in the diagnosis and management of gestational diabetes mellitus in the United States. The Journal Of Maternal-Fetal & Neonatal Medicine, 1–6. doi: 10.1080/14767058.2016.1257603.

Koren, R., Ashwal, E., Hod, M., & Toledano, Y. (2016). Insulin detemir versus glyburide in women with gestational diabetes mellitus. Gynecological Endocrinology, 32(11), 916–919. doi: 10.1080/09513590.2016.1209479.

Lamkanfi, M., Mueller, J., Vitari, A., Misaghi, S., Fedorova, A., Deshayes, K. et al. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal Of Cell Biology, 187(1), 61–70. doi: 10.1083/jcb.200903124.

Masters, S., Dunne, A., Subramanian, S., Hull, R., Tannahill, G., & Sharp, F. et al. (2010). Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunology, 11(10), 897–904. doi: 10.1038/ni.1935.

Hughes, F. M. Jr., Kennis, J. G., Youssef, M. N., Lowe, D. W., Shaner, B. E., & Purves, J. T. (2016). The NACHT, LRR and PYD Domains-Containing protein 3 (NLRP3) Inflammasome Mediates Inflammation and Voiding Dysfunction in a Lipopolysaccharide-Induced Rat Model of Cystitis. Journal Of Clinical & Cellular Immunology, 07(01). doi: 10.4172/2155-9899.1000396.

Schroder, K., & Tschopp, J. (2010). The Inflammasomes. Cell, 140(6), 821–832. doi: 10.1016/j.cell.2010.01.040.

Lawlor, K., & Vince, J. (2014). Ambiguities in NLRP3 inflammasome regulation: Is there a role for mitochondria? Biochimica Et Biophysica Acta (BBA) - General Subjects, 1840(4), 1433–1440. doi: 10.1016/j.bbagen.2013.08.014.

Patel, M., Carroll, R., Galván-Peña, S., Mills, E., Olden, R., Triantafilou, M. et al. (2017). Inflammasome Priming in Sterile Inflammatory Disease. Trends In Molecular Medicine, 23(2), 165–180. doi: 10.1016/j.molmed.2016.12.007.

Pellegrini, C., Antonioli, L., Lopez-Castejon, G., Blandizzi, C., & Fornai, M. (2017). Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. Frontiers In Immunology, 8, 36. doi: 10.3389/fimmu.2017.00036.

Doitsh, G., Galloway, N., Geng, X., Yang, Z., Monroe, K., Zepeda, O., et al. (2013). Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 505(7484), 509–514. doi: 10.1038/nature12940.

Arbore, G., West, E., Spolski, R., Robertson, A., Klos, A., Rheinheimer, C., et al. (2016). T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science, 352(6292), aad1210. doi: 10.1126/science.aad1210.

Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., et al. (2015). The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nature Immunology, 16(8), 859–70. doi: 10.1038/ni.3202.

Kumar, P., & Subramaniyam, G. (2015). Molecular underpinnings of Th17 immune-regulation and their implications in autoimmune diabetes. Cytokine, 71(2), 366–376. doi: 10.1016/j.cyto.2014.10.010.

Chung, Y., Chang, S., Martinez, G., Yang, X., Nurieva, R., Kang, H., et al. (2009). Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 Signaling. Immunity, 30(4), 576–587. doi: 10.1016/j.immuni.2009.02.007.

Mailer, R., Joly, A., Liu, S., Elias, S., Tegner, J., & Andersson, J. (2015). IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3. Scientific Reports, 5, 14674. doi: 10.1038/srep14674.

Schroder, K., Zhou, R., & Tschopp, J. (2010). The NLRP3 Inflammasome: A Sensor for Metabolic Danger? Science, 327(5963), 296–300. doi: 10.1126/science.1184003.

Hu, C., Ding, H., Li, Y., Pearson, J., Zhang, X., Flavell, R., et al. (2015). NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proceedings Of The National Academy Of Sciences, 112(36), 11318–11323. doi: 10.1073/pnas.1513509112.

Pontillo, A., Brandao, L., Guimaraes, R., Segat, L., Araujo, J., & Crovella, S. (2010). Two SNPs inNLRP3gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity, 43(8), 583–589. doi: 10.3109/08916930903540432.

Carlos, D., Costa, F., Pereira, C., Rocha, F., Yaochite, J., Oliveira, G., et al. (2017). Mitochondrial DNA Activates the NLRP3 Inflammasome and Predisposes to Type 1 Diabetes in Murine Model. Frontiers In Immunology, 8, 164. doi: 10.3389/fimmu.2017.00164.

Volpe, C., Anjos, P., & Nogueira-Machado, J. (2016). Inflammasome as a New Therapeutic Target for Diabetic Complications. Recent Patents On Endocrine, Metabolic & Immune Drug Discovery, 10(1), 56–62. doi: 10.2174/1872214810666160219163314.

Lamprianou, S., Gysemans, C., Bou Saab, J., Pontes, H., Mathieu, C., & Meda, P. (2016). Glibenclamide Prevents Diabetes in NOD Mice. PLoS One, 11(12), e0168839. doi: 10.1371/journal.pone.0168839.

Downloads

How to Cite

1.
Prozorova ТМ, Kamyshna VA, Kamyshnyi ОМ. Effect of experimental gestational diabetes and administration of glibenclamide on mRNA level of NLRP3-inflammasome and distribution of NLRP3+-cells in mesenteric lymph nodes in progeny. Pathologia [Internet]. 2017Sep.27 [cited 2024Dec.5];(2). Available from: http://pat.zsmu.edu.ua/article/view/109269

Issue

No. 2 (2017)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).